A patient died after receiving Pfizer Inc.’s drug for hemophilia, marking another setback for the company in the treatment of ...

Pfizer disclosed a patient death in a marstacimab hemophilia study, triggering a safety review and reassessment of surgical ...

Pfizer Inc. (NYSE:PFE) is one of the best high volume stocks to buy right now. On December 16, Bank of America analyst Jason Gerberry lowered the firm’s price target on Pfizer to $27 from $28 while ...

Pfizer Inc. forecast little to no sales growth next year as the drugmaker undertakes an effort to refresh its pipeline of hit ...

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

FDA approves a new Depo-Provera warning on meningioma risk as Pfizer faces lawsuits alleging delayed disclosure of brain ...

As of the close of business on December 5, around 60% of the 26 Wall Street analysts with recommendations on Pfizer have a Hold rating for the stock. The pharmaceuticals company has a one-year average ...

Pfizer is pursuing pipeline expansions through the Metsera acquisition and a major licensing deal with 3SBio. Find out why ...

Explore Pfizer Inc.’s 2025-2026 outlook: challenges, flat revenues, patent risks, and potential from the Metsera deal. Click ...

Pfizer Inc. is cutting hundreds of jobs in Switzerland as part of a multi-year program to reduce costs, according to people ...

Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 first-quarter 2026 dividend on the ...

Pfizer Inc. (NYSE:PFE)’s shares are down by 5.90% year-to-date, and December has been a tumultuous month for them.